RHYTHM PHARMACEUTICALS, INC. Proceeds from Long-Term Debt Issued
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Proceeds from Long-Term Debt Issued of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-02-26
- RHYTHM PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for the quarter ending 2023-12-31 was $0.00.
- RHYTHM PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for the quarter ending 2022-12-31 was -$2.66M.
- RHYTHM PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for the quarter ending 2022-09-30 was $37.50M.
- RHYTHM PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for fiscal 2025 was $0.00.
- RHYTHM PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- RHYTHM PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for fiscal 2023 was $24.37M, a 66.31% decline from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for fiscal 2022 was $72.34M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $24.37M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $24.37M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | -$2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $34.84M derived: sum of 2 quarters · filed 2025-02-28 | $72.34M 10-K · filed 2025-02-28 | |
| 2022-09-30 | $37.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $75.00M 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $37.50M 10-Q · filed 2023-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |